过氧化物酶体增殖物激活受体：一类核受体在多种疾病中的作用。
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.
作者信息
Tyagi Sandeep, Gupta Paras, Saini Arminder Singh, Kaushal Chaitnya, Sharma Saurabh
机构信息
Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.
出版信息
J Adv Pharm Technol Res. 2011 Oct;2(4):236-40. doi: 10.4103/2231-4040.90879.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ causes insulin sensitization and enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism. Thus, PPAR family of nuclear receptors plays a major regulatory role in energy homeostasis and metabolic function. The present review critically analyzes the protective and detrimental effect of PPAR agonists in dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, fertility or reproduction, pain, and obesity.
摘要
过氧化物酶体增殖物激活受体（PPARs）是核激素受体超家族的配体激活转录因子，包括以下三种亚型：PPARα、PPARγ和PPARβ/δ。PPAR-α的激活可降低甘油三酯水平，并参与能量稳态的调节。PPAR-γ的激活可导致胰岛素敏感性增加并增强葡萄糖代谢，而PPAR-β/δ的激活则可增强脂肪酸代谢。因此，核受体PPAR家族在能量稳态和代谢功能中起主要调节作用。本综述批判性地分析了PPAR激动剂在血脂异常、糖尿病、脂肪细胞分化、炎症、癌症、肺部疾病、神经退行性疾病、生育或生殖、疼痛和肥胖中的保护作用和有害作用。
相似文献
1
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.
J Adv Pharm Technol Res. 2011 Oct;2(4):236-40. doi: 10.4103/2231-4040.90879.
2
PPAR dual agonists: are they opening Pandora's Box?
Pharmacol Res. 2007 Aug;56(2):91-8. doi: 10.1016/j.phrs.2007.03.002. Epub 2007 Mar 14.
3
Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Neurochem Int. 2013 Oct;63(4):322-30. doi: 10.1016/j.neuint.2013.06.012. Epub 2013 Jun 25.
4
The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.
Exp Eye Res. 2021 Jul;208:108617. doi: 10.1016/j.exer.2021.108617. Epub 2021 May 16.
5
Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
Swiss Med Wkly. 2010 Sep 15;140:w13071. doi: 10.4414/smw.2010.13071. eCollection 2010.
6
Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Curr Diabetes Rev. 2005 Aug;1(3):299-307. doi: 10.2174/157339905774574365.
7
Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications.
Pharmaceutics. 2022 Oct 8;14(10):2139. doi: 10.3390/pharmaceutics14102139.
8
The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.
Mol Endocrinol. 2003 Dec;17(12):2477-93. doi: 10.1210/me.2003-0151. Epub 2003 Oct 2.
9
Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Mol Pharmacol. 2009 Aug;76(2):414-24. doi: 10.1124/mol.109.056010. Epub 2009 May 29.
10
Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
Int J Mol Sci. 2023 Jan 25;24(3):2345. doi: 10.3390/ijms24032345.
引用本文的文献
1
Oral Pharmacokinetic Evaluation of a Microemulsion-Based Delivery System for Novel A190 Prodrugs.
Biomolecules. 2025 Jul 30;15(8):1101. doi: 10.3390/biom15081101.
2
Sputum Transcriptomic Analysis and Clustering Reveals Insight Into Asthma Heterogeneity.
Lung. 2025 Aug 20;203(1):89. doi: 10.1007/s00408-025-00843-1.
3
Imaging Ligand-Driven PPAR Activities Using Single-Chain Bioluminescent Probes.
ACS Omega. 2025 Jul 24;10(30):33850-33861. doi: 10.1021/acsomega.5c04665. eCollection 2025 Aug 5.
4
In silico and in vitro investigations reveal pan-PPAR agonist activity and anti-NAFLD efficacy of polydatin by modulating hepatic lipid-energy metabolism.
Sci Rep. 2025 Jul 24;15(1):26995. doi: 10.1038/s41598-025-12357-0.
5
PPARG-centric transcriptional re-wiring during differentiation of human trophoblast stem cells into extravillous trophoblasts.
Nucleic Acids Res. 2025 Jul 19;53(14). doi: 10.1093/nar/gkaf669.
6
Exploring chemical constituents and anti-inflammatory mechanisms of Semiaquilegiae Radix via an integrated strategy combining UHPLC-Q-TOF-MS analysis, network pharmacology and molecular docking.
Saudi Pharm J. 2025 Jul 8;33(4):19. doi: 10.1007/s44446-025-00012-8.
7
Role of Nutritional Elements in Skin Homeostasis: A Review.
Biomolecules. 2025 Jun 3;15(6):808. doi: 10.3390/biom15060808.
8
Obesity drives depot-specific vascular remodeling in male white adipose tissue.
Nat Commun. 2025 Jun 25;16(1):5392. doi: 10.1038/s41467-025-60910-2.
9
Review on Advancement of AI in Nutrigenomics.
Methods Mol Biol. 2025;2952:429-444. doi: 10.1007/978-1-0716-4690-8_23.
10
Microglial phagocytosis in epilepsy: Mechanisms and impact.
J Physiol. 2025 Jun 18. doi: 10.1113/JP288573.
本文引用的文献
1
PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.
Nucl Recept Signal. 2010 Apr 16;8:e004. doi: 10.1621/nrs.08004.
2
New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Breast Cancer Res Treat. 2010 Nov;124(1):101-10. doi: 10.1007/s10549-009-0700-y. Epub 2010 Jan 7.
3
PPAR research: Successful launching and promising future.
PPAR Res. 2009;2009:543584. doi: 10.1155/2009/543584. Epub 2009 Jul 30.
4
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia.
Eur J Pharmacol. 2009 Jun 24;613(1-3):54-9. doi: 10.1016/j.ejphar.2009.04.022. Epub 2009 Apr 20.
5
Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury.
J Pharmacol Sci. 2008 Nov;108(3):341-7. doi: 10.1254/jphs.08207fp. Epub 2008 Nov 13.
6
PPARs in Neuroinflammation.
PPAR Res. 2008;2008:638356. doi: 10.1155/2008/638356.
7
Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats.
J Cell Mol Med. 2009 Jun;13(6):1086-95. doi: 10.1111/j.1582-4934.2008.00353.x. Epub 2008 Apr 18.
8
Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.
J Pain. 2008 Jul;9(7):639-49. doi: 10.1016/j.jpain.2008.02.002. Epub 2008 Apr 3.
9
Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men.
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1050-9. doi: 10.1161/ATVBAHA.107.158998. Epub 2008 Mar 6.
10
Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
Curr Diabetes Rev. 2007 Feb;3(1):33-9. doi: 10.2174/157339907779802067.
Zotero 插件